BOSUVI 400MG TAB

BOSUVI 400MG TAB is a prescription medication that contains 400mg of Bosutinib, a tyrosine kinase inhibitor used in the treatment of various types of cancer, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is available in tablet form.

Composition:

BOSUVI 400MG TAB contains 400mg of Bosutinib, a white to off-white powder.

Mechanism of Action:

Bosutinib works by:

• Inhibiting the activity of BCR-ABL, a protein that is involved in the growth and proliferation of cancer cells
• Inhibiting the activity of other tyrosine kinases, such as Src and Abl
• Inducing apoptosis (cell death) in cancer cells

Indication:

BOSUVI 400MG TAB is indicated for:

• Treatment of adults with CML or Ph+ ALL who have failed prior therapy or have relapsed after previous treatment

Dosage:

The recommended dosage of BOSUVI 400MG TAB is:

• 400mg orally once daily, taken at the same time each day
• Dose adjustments may be necessary based on patient response and toxicity

Side Effects:

Common side effects of BOSUVI 400MG TAB may include:

• Diarrhea
• Fatigue
• Nausea and vomiting
• Rash
• Increased risk of infections
• Gastrointestinal toxicity (stomatitis, esophagitis)
• Hepatotoxicity (elevated liver enzymes)

Recommendation:

BOSUVI 400MG TAB should only be used under the guidance of a healthcare provider. Patients receiving BOSUVI 400MG TAB treatment should be closely monitored for side effects and potential complications.

Important Note:

• BOSUVI 400MG TAB is a potent medication that can cause serious side effects, including diarrhea and hepatotoxicity. Patients should be closely monitored for these side effects.
• Patients with a history of severe allergic reactions to bosutinib or other tyrosine kinase inhibitors should not receive BOSUVI 400MG TAB.
• Patients with a history of severe kidney disease or severe liver disease should be closely monitored while receiving BOSUVI 400MG TAB.

Special Precautions:

• Patients with a history of severe gastrointestinal disorders should be closely monitored while receiving BOSUVI 400MG TAB.
• Patients with a history of bone marrow suppression or other bone marrow disorders should be closely monitored while receiving BOSUVI 400MG TAB.

It is important to note that the dosage and administration of BOSUVI 400MG TAB may vary depending on the patient’s individual needs and medical history. It is recommended that patients consult their healthcare provider before taking this medication.